Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
"I have no idea why you’ve started to frequent this board with your fanciful posts but I do know it’s more for your own amusement than it is to provide the down trodden investors here with something insightful and useful."
Who could it be?
"I have no idea why you’ve started to frequent this board with your fanciful posts but I do know it’s more for your own amusement than it is to provide the down trodden investors here with something insightful and useful."
HE KICKS HE SCORES!!!!1!
It's been confirmed. Axe_Capital is RS aka Org.
Pretending to be mentioned in dispatches, mentioned in The Times, and a decorated war hero risking all for his country while in reality working in a comfy office.
Uber Walt.
Gunto2022
"The tests will present the bio markers that will guide the selection (stratification) of patients. Aether, it is the test itself that is holding up the trials I think, not the lack of bio marker data. SNG are working with an unknown partner on the test."
The test relies on the bio-markers to be effective. I think it's the fact that they don't have the bio-markers that is the challange. Maybe! That is why UNIVERSAL is important. Clarification is needed on this important point.
Doc.Dan
"Hopefully we'll see the P2 protocols before Christmas - and maybe get an update on the UNIVERSAL bio-marker assessments we were promised. The first set of data from UNIVERSAL was not particularly helpful. Or at least it didn't contain any of the real juice that will inform the trial designs."
Bio-markers are essential for the success of the P2s.
They enable the appropriate patients to be identified.
If the company don't have bio-markers to enable this, whether from UNIVERSAL or elsewhere, the P2s will probably be further delayed.